
Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsJohnson & Johnson Builds AI-Powered Surgical Network in Abu DhabiPexels Johnson & Johnson MedTech and the Department of Health – Abu Dhabi have launched the world’s first global hub…Fact-Checked
Mergers & AcquisitionsBMS Integrates Claude AI into Research, Clinical Development, and ManufacturingBristol Myers Squibb has expanded its enterprise AI strategy through a collaboration with Anthropic, rolling out Claude to more than 30,000 employees.Fact-Checked
Mergers & AcquisitionsIncyte Expands Molecular AI Collaboration With Genesis TherapeuticsIncyte and Genesis Therapeutics have broadened their strategic collaboration to accelerate AI-driven small molecule drug discovery.Fact-Checked
Mergers & AcquisitionsHansa Licenses IDEFIRIX Rights to SERB in €115 Million DealHansa Biopharma signed an exclusive licensing agreement with SERB for the development and commercialization of IDEFIRIX across Europe and MENA.Fact-Checked
Mergers & AcquisitionsIncyte Collaborates With Edison Scientific on AI-Driven Drug DiscoveryIncyte has partnered with Edison Scientific to deploy the AI platform Kosmos across its research and development operations.Fact-Checked
Mergers & AcquisitionsRegeneron and Parabilis Partner to Develop Antibody-Helicon ConjugatesRegeneron partnered with Parabilis Medicines to develop Antibody-Helicon Conjugates, investigational therapies that combine antibody targeting with intracellular Helicon peptide delivery for historically “undruggable” proteins.Fact-Checked
Mergers & AcquisitionsImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG for Bladder CancerImmunityBio signed an exclusive agreement with Japan BCG Laboratory to develop and commercialize Tokyo-172 BCG in the United States after Phase III SWOG S1602 data demonstrated non-inferiority to…Fact-Checked
Mergers & AcquisitionsEli Lilly and UNICEF USA Strengthen Childhood NCD Care in LMICsEli Lilly and Company will invest $50 million over six years to support UNICEF USA programs focused on strengthening healthcare systems, improving early diagnosis, and expanding long-term care…Fact-Checked
Mergers & AcquisitionsEnodia Therapeutics Acquires Sec61-Based Assets from Kezar Life SciencesEnodia Therapeutics acquired Kezar Life Sciences’ Sec61 program assets, including KZR-261, in a transaction featuring $1 million upfront and up to $127 million in milestone payments to advance…Fact-Checked
Mergers & AcquisitionsBoehringer Ingelheim Licenses Preclinical Antibody from Immunitas for Inflammatory DiseasesBoehringer Ingelheim inks global deal with Immunitas Therapeutics for a novel preclinical antibody targeting chronic inflammatory diseases.Fact-Checked
Mergers & AcquisitionsRigel Acquires Global Rights to Arvinas and Pfizer’s VEPPANURigel Pharmaceuticals secured exclusive global rights to VEPPANU (vepdegestrant) from Arvinas and Pfizer, taking over commercialization of the first FDA-approved PROTAC therapy for ESR1-mutated ER+/HER2- advanced breast cancer.…Fact-Checked
Mergers & AcquisitionsBMS and Hengrui Forge a $15.2 Billion Drug Discovery AllianceUnsplash Bristol Myers Squibb and Hengrui Pharma entered a global strategic collaboration covering 13 early-stage oncology, hematology, and immunology programs…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.